Outcomes in clinical trials of inhaled corticosteroids for children with asthma are narrowly focussed on short term disease activity. by Sinha, IP et al.
Outcomes in Clinical Trials of Inhaled Corticosteroids for
Children with Asthma Are Narrowly Focussed on Short
Term Disease Activity
Ian P. Sinha1*, Paula R. Williamson2, Rosalind L. Smyth1
1 Institute of Child Health, University of Liverpool, Liverpool, United Kingdom, 2Centre for Medical Statistics and Health Evaluation, University of Liverpool, Liverpool,
United Kingdom
Abstract
Background: Little work has been done to determine which outcomes should be measured in randomised controlled trials
(RCTs) in children with asthma. Drug regulatory authorities require that short term disease activity is measured, but other
outcome domains are not mandatory for licensing and marketing purposes. We aimed to identify whether any domains
were underrepresented in RCTs of regular therapies for children with asthma over a 20 year period, and to examine what
consistency there was between RCTs in the outcomes used to assess the domains.
Methodology/Principal Findings: By searching the Cochrane Central Register of Controlled Trials in January 2008, we
identified all parallel-group RCTs, published between January 1988 and December 2007, which assessed inhaled
corticosteroids (ICS) as regular therapy for children with asthma. We evaluated how frequently RCTs measured the following
pre-defined domains: disease activity; disease damage; functional status; quality of life; health resource utilisation; and
adverse effects of therapy. Our initial search identified 1668 abstracts, of which 412 were retrieved in full. 159 RCTs, of which
115 involved only children and 44 involved children and adults, were included in the review. Disease activity was measured
in 157 RCTs, adverse effects of ICS in 135, functional status in 25, quality of life in 21, and health resource utilisation in 17. No
RCT measured long term disease damage, although two used FEV1 as a measure of ‘lung growth’. RCTs were inconsistent in
the outcomes used to measure the domains.
Conclusions: Short term disease activity is the most frequently measured outcome domain in RCTs in children with asthma.
Effects of regular therapies on functional status, quality of life, and long term consequences of asthma are infrequently
assessed. A core set of outcomes, developed using consensus techniques, would standardise the measurement of
appropriate outcomes in these RCTs. Involving patients would identify outcomes which are most relevant from their
perspective.
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Introduction
Asthma in children is a major global health problem [1],
because it is an important cause of morbidity, mortality and
economic cost [2], it is the commonest chronic condition in
industrialised countries [3], its prevalence is increasing [4], and in
many children it is a progressive condition that continues into
adulthood [5].
The first line of regular therapy for the control of asthma in
children is inhaled corticosteroids (ICS), and recommended
additional treatments are long acting beta-2 agonists and
leukotriene receptor antagonists [6]. Randomised controlled trials
(RCTs) are the most scientifically rigorous method for evaluating
the efficacy and safety of these medications [7], but it can be
difficult to select the most appropriate outcomes to measure in
these studies, because asthma impacts on many aspects of the lives
of children. For example, the effects of treatment could include
improvement of daily symptoms, quality of life, or physiological
tests of lung function such as Forced Expiratory Volume in
1 second (FEV1) or Peak Expiratory Flow Rate (PEFR) [8].
We previously published a systematic review, of studies that
determined which outcomes should be measured in clinical trials
in children [9]. In this review, we proposed that outcomes
measured in RCTs that include children should be considered
under six domains: short term measures of disease activity,
physical consequence of disease, functional status, family outcomes
and quality of life, side effects of therapy and health resource
utilisation. We found one study that addressed the outcomes used
in clinical trials of regular therapies for childhood asthma, in which
the authors ascertained, by questionnaire, the opinions of 14
specialists and researchers about outcomes relating to disease
activity, functional status, and quality of life [10]. As this study
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consulted only a limited group of experts, and did not use
recognised consensus techniques, it does not provide a robust basis
for recommendations about which domains and outcomes are
most appropriate for RCTs of children with asthma.
There have been initiatives to standardise the outcomes which are
measured in clinical trials of other conditions. The most notable is the
OMERACT collaboration, an international network of clinicians
and patients, initially formed in response to the observation that
clinical trials of patients with rheumatoid arthritis conducted in the
USA measured different outcomes to those conducted in Europe.
OMERACT uses structured consensus techniques to determine
which outcomes should be measured in clinical trials in a variety of
rheumatological conditions [11–13]. Initiatives such as these increase
the likelihood that all important outcome domains are measured,
reduce the measurement of inappropriate outcomes [14], and aid
comparison and synthesis of findings between different clinical trials
[15,16]. It has also been suggested that arbitrary or inconsistent
outcome selection may lead to clinical trials with unnecessarily large
sample sizes [17] and reporting biases [17,18].
The aim of this systematic review was to assess which outcomes
had been measured in clinical trials of ICS in children with
chronic asthma between 1988 and 2007, in order to determine
whether all relevant domains were represented, and whether there
was consistent selection of outcomes within these domains.
Secondary objectives were to determine whether the selection of
outcome domains has changed between 1988 and 2007, whether
domains measured in RCTs exclusively involving children differ
from those in studies involving both children and adults, and
whether domains measured in publically funded trials differed
from those in trials funded by the pharmaceutical industry.
Methods
Included studies
In order to ensure that we assessed a group of similar studies, we
limited this review to include only RCTs with parallel group
design that assessed ICS as a therapy to prevent symptoms or long-
term effects of asthma in children. We excluded crossover trials
because they are generally of acute interventions, the length of
treatment in these studies is typically shorter, and the outcomes
they measure may differ from those measured in parallel trials
[19]. In order to only include RCTs assessing long term
preventative therapy for asthma, we excluded studies with a
treatment phase of less than one month. The review was restricted
to studies published between January 1988 and December 2007.
Identification of studies
Using the abbreviated search strategy ‘children AND inhaled
corticosteroids AND asthma’, the Cochrane Central Register of
Controlled Trials was searched in January 2008. This database
comprises RCTs from MEDLINE, and also from conference
proceedings and journals not indexed in MEDLINE. The
references of identified studies were also screened for other
potentially eligible studies. The full search strategy is included in
supplementary File S1. One reviewer (IS) assessed trial eligibility,
under the supervision of the senior authors (PRW and RLS).
Data extraction and quality assessment
The same reviewer extracted the following data, and any
problems were resolved by discussion with the other two authors:
1. All outcomes measured in the trial
2. If stated, the designated primary outcome, and whether this
was described in sufficient detail, including the methods used to
measure it, by whom, and when it was measured and analysed.
3. Masking of interventions was examined because the extent
to which interventions were masked may affect the choice of
outcomes, and whether they were measured objectively or
subjectively. The adequacy of masking was categorised as follows.
Adequately masked. Authors either clearly describe or
imply, in the methods, how the allocated treatment was masked
to the patient and family, medical caregiver, and relevant trial
personnel involved in measuring outcomes.
Inadequately masked. Authors specifically state that the
identity of the allocated treatment arm was not masked to at least
one of the following: patient and family, medical caregiver, or
relevant trial personnel involved in measuring outcomes.
Unclear. Unclear from study methods whether masking was
adequate or not.
4. Other study features: year of publication; interventions
compared; ages of children included; length of study treatment;
source of funding; single- or multi-centre
Data analysis and presentation
For each study that included exclusively children, the data were
tabulated and each outcome was grouped into one of the following
six outcome domains, some of which were further divided into
subdomains [9]: disease activity, physical consequence of disease,
functional status, social outcomes and quality of life, side effects of
therapy and health resource utilisation. Where it was unclear
which domain was appropriate, this was resolved by discussion
between the authors.
To assess how the selection of outcomes has changed over time,
we divided the period 1988 to 2007 into sixteen separate epochs,
each lasting five years. In each epoch we calculated the proportion
of studies measuring each outcome domain, and we presented the
results as a moving window.
Results
Flow of included studies
The search yielded 1668 potentially eligible reports. Of these,
1256 were excluded by reading the abstract. The remaining 412
were retrieved in full, and 203/412 were subsequently excluded.
In total, 209 eligible reports, of 159 RCTs, were included in the
review. The review flowchart is shown in Figure 1. Included
studies are listed in supplementary File S2.
Description of included studies
Of the 159 studies included in this review, 115 exclusively
included children, and 44 included children and adults.
The characteristics of included studies are summarised in
Table 1. Within the group of studies that included only children,
all paediatric age groups were represented, but only 25/115 (21%)
included children younger than four years of age. In the studies of
adults and children, 42/44 (95%) included children aged between
12 and 18 years of age, but not younger than 12, and 2/44 (5%)
included children between 5 and 18 years of age, but not younger
than 5.
83/159 (52%) included a comparison between ICS groups
(either different doses, modes of delivery, or different types of ICS
eg fluticasone vs beclomethasone), 63/159 (40%) included a
comparison with placebo, and 54/159 (34%) included a
comparison with another drug.
Masking of interventions was deemed adequate in 121/159
studies (76%), inadequate in 33/159 (21%), and unclear in 5/159
(3%). Of the 33 studies that were classed as inadequately masked,
18 compared ICS with another drug, 8 compared ICS
administered by different devices, 3 compared one ICS to another,
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3 compared ICS administered using different dosing schedules,
and 1 compared ICS with no treatment. Subjective outcomes that
could have been affected by the lack of blinding were measured in
29/33 of these studies (29/33 measured symptoms, 8/33
measured quality of life and 6/33 measured functional status).
Outcome domains which were measured in the studies
Disease activity was measured in 157/159 (99%) studies,
adverse effects of therapy in 135/159 (85%), functional status in
25/159 (16%), quality of life in 21/159 (13%), and health resource
utilisation in 17/159 (11%). No studies measured the effects of ICS
on long-term physical consequences of asthma, although two
studies measured post-bronchodilator FEV1, as a percentage of
the predicted value, to assess ‘lung growth’. In one of these studies
children, aged between 5 and 12 years, were randomised to
receive inhaled budesonide, nedocromil sodium or placebo for a
period of four to six years, and FEV1was measured as the primary
outcome [20]. In the other study, patients aged between 5 and 66
years were randomised to treatment with inhaled budesonide or
placebo for three years, and FEV1 was measured as a secondary
outcome [21]. Similar outcome domains were represented in the
115 studies that included only children and the 44 that included
children and adults.
There was a wide variety of outcomes within individual
domains. This was greatest for the disease activity domain, which
was divided into five subdomains (clinical measures, physiological
tests of lung function, global measures, bronchial responsiveness to
a challenge agent or exercise and markers of inflammation), each
of which included outcomes measured in different ways. As can be
seen in Table 2, the selection of subdomains and outcomes was
inconsistent across the studies.
Primary outcomes
The primary outcomes measured in the RCTs that included
only children are listed in Table 2. It was possible to determine the
primary outcome in 84/115 (73%) studies. In 64 of these, the
primary outcome was clearly stated by the authors, and in the
remaining 20 it was inferred from the outcome used to calculate
the sample size. Five studies each selected two co-primary
outcomes. Of the 84 studies that specified a primary outcome,
74 (88%) selected primary outcomes that measured disease
activity. A total of 17 different primary outcomes were selected,
of which physiological measures of airway obstruction, including
PEFR (26 studies) and FEV1 (16 studies), were the most frequent.
None of the primary outcomes addressed the functional status or
quality of life domains
It was possible to determine the primary outcome in 39/44
(89%) studies that included children and adults. In 34 of these, the
primary outcome was clearly stated by the authors, and in the
remaining 5 it was inferred from the outcome used to calculate the
required sample size. In 38/39 (97%), was some measure of
disease activity. The most widely used primary outcome was FEV1
(28 studies).
Outcomes measured in studies funded by the
pharmaceutical industry
The frequency with which most domains were measured in the
127 studies sponsored by the pharmaceutical industry was similar
to the 32 publicly funded studies. The main difference we observed
was that adverse effects of therapy were measured in a higher
proportion of studies sponsored by the pharmaceutical industry
(118/127, 93%) compared to studies funded from other sources
(17/32, 53%).
How the selection of outcome domains has changed
over time
The trend over the period January 1988 to December 2007 in
the selection of outcome domains in RCTs including only children
is shown in Figure 2. Disease activity and adverse effects of therapy
have remained consistently frequently measured outcome do-
mains. Since the 1992–1996 epoch the proportion of studies
measuring functional status, for example by assessing school
absence due to asthma, has decreased from 40% to 10%, and
those measuring quality of life have increased from 10% to 25%.
Discussion
We found that RCTs in children with asthma almost always
assess the effects of therapies on short term disease activity, but
none consider the effects on long term progression of disease.
Quality of life and functional status are measured infrequently.
While there were similarities between studies, particularly in the
selection of primary outcomes that measure disease activity, other
outcomes showed wide variability.
The pharmaceutical industry funded 80% of the RCTS we
identified, and so it is not surprising that the frequency with which
outcomes in the disease activity domain have been measured as
primary or secondary outcomes reflects, to some extent, the
requirements of the FDA [22,23] and EMEA [24–27]. These
authorities recommend, for the purpose of drug licensing and
marketing authorisation, that risks and benefits of preventative
therapies for children with asthma are assessed in clinical trials that
measure, as primary outcomes, physiological tests of pulmonary
function and clinical measures such as symptom scores. Other
measures of short term disease activity, such as use of rescue
medication, rate of exacerbations, and bronchial hyper-respon-
Figure 1. Study flowchart. Flowchart shows the number of abstracts
identified by the search, the number of full texts retrieved, and the
number of studies included in the review.
doi:10.1371/journal.pone.0006276.g001
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siveness are suggested as important outcomes. Quality of life and
exercise tolerance are mentioned as additional outcomes that may
provide useful information, but no clear recommendations have
been made regarding the use of these outcomes [25].
It is disappointing that, despite the use of ICS in childhood
asthma for more than twenty years, their effects on functional
status, quality of life, and long term consequences of asthma
remain largely unknown. Markers of short-term disease activity,
despite their prominence in drug regulatory guidelines and
popularity amongst trialists, have been shown to correlate poorly
with quality of life [28–30], and are therefore not appropriate
surrogate markers for aspects of asthma that could be of more
relevance to patients.
Given that the aim of an RCT is to evaluate the safety and
efficacy of interventions, and provide some assessment of whether
the intervention does more good than harm, it is disappointing to
note that quality of life and family outcomes are only measured in
20% of RCTs, and that the impact of disease on functional status is
now measured in less than 10%. We identified no clinical trials in
which the primary outcome measured these domains. In studies that
have investigated which outcomes are clinically relevant to patients
with other conditions, such as chronic pain [31], fibromyalgia [32],
and rheumatoid arthritis [33], measures of functional status and
quality of life were identified as being of great importance, and it is
likely that this is the case in children with asthma.
Functional status overlaps with quality of life and disease
activity. However, we feel that measures of functional status are
important, distinct, markers of how asthma affects children. In
clinical trials in adults with chronic illnesses, absence from work is
an important outcome, and we feel that an appropriate childhood
equivalent would include measures of school attendance and other
activities of daily living.
It is particularly important in trials of children to assess the
impact of treatments in the long term. Very few studies have
Table 1. Characteristics of included studies.
Study characteristic Category
Number (%) of studies
which included only
children (n =115)
Number (%) of studies
which included
children and adults
(n =44)
Date of publication January 1988 to December 1992 10 (9) 1 (2)
January 1993 to December 1997 19 (17) 5 (11)
January 1998 to December 2002 48 (42) 22 (50)
January 2003 to December 2007 38 (32) 16 (37)
Length of treatment period 1 to 3 months 30 (26) 5 (11)
3 to ,6 months 46 (40) 30 (69)
6 to ,12 months 13 (11) 4 (9)
12 months or longer 24 (21) 5 (11)
Unclear 2 (2) 0
Age groups of children included ,4 years only 17 (15) 0
,4 and 4 to ,12 years 7 (6) 0
,4 and 4 to,12 and 12 to 18 years 1 (1) 0
4 to ,12 years only 36 (31) 0
4 to ,12 years and 12 to 18 years 53 (46) 2 (5)
12 to 18 years only 1 (1) 42 (95)
Number of centres Multicentre 75 (65) 42 (95)
Single centre 39 (34) 2 (5)
Unclear 1 (1) 0
Source of funding Industry 85 (74) 42 (95)
Public funding bodies 30 (26) 2 (5)
Comparisons ICS vs Other drug 26 (23) 12 (27)
ICS vs placebo 25 (22) 4 (9)
ICS 1 vs ICS 2 14 (12) 3 (7)
ICS vs same ICS (different delivery device) 12 (10) 2 (5)
ICS vs same ICS (different dose) 9 (8) 3 (7)
ICS vs no treatment 1 (1) 0
ICS 1 vs ICS 2 vs Placebo 16 (14) 10 (23)
ICS 1 vs ICS 2 vs Other drug 7 (6) 1 (2)
ICS vs Other drug vs placebo 4 (3) 4 (9)
ICS vs same ICS (different dose and mode) 1 (1) 0
ICS 1 vs ICS 1 (different dose) vs ICS 2 0 5 (11)
doi:10.1371/journal.pone.0006276.t001
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Table 2. Frequency with which outcome domains, and outcomes used to measure them, were selected in 115 trials involving only
children published between 1988 and 2008.
Domain Subdomain 1 Subdomain 2 Outcome
Number (%) of
studies in which
measured as
primary or
secondary
outcome
n=115
Number (%)
of studies
in which
measured as
primary
outcome
n=84a
Disease activity 114 (99) 74 (88)
Clinical measures n = 109 Symptoms Symptom severity 90 (77) 10 (12)
Symptom frequency 55 (47) 5 (6)
Use of rescue therapy 90 (77) 2 (2)
Exacerbations Exacerbation frequency 35 (30) 4 (5)
Time to exacerbation 10 (9) 0
Tests of lung function n = 103 Spirometry FEV1 80 (70) 16 (19)
FVC 31 (26) 0
Mid expiratory flow 23 (20) 0
FEV1:FVC 6 (5) 0
FEV1 reversibility 9 (8) 0
PEFR PEFR 85 (73) 26 (31)
Diurnal variability 13 (11) 0
Day-to-day variability 5 (4) 0
Lung volume Plethysmographic 4 (3) 0
Airway flow Resistance/conductance 5 (4) 2 (2)
Global measure of control n = 29 Physician-rated 8 (7) 1 (1)
Parent/patient – rated 14 (12) 0
‘Treatment failure’ 13 (11) 0
‘Treatment success’ 3 (3) 0
Bronchial responsiveness to a
challenge agent n = 29
Induced BHR Methacholine-induced 26 (22) 6 (7)
Exercise-induced 7 (6) 0
Markers of inflammation n = 20 Exhaled nitric oxide 5 (4) 1 (1)
Leukotrieneb/interleukinc 4 (3) 1 (1)
Eosinophilsd/IgEe 18 (15) 0
Physical consequence
of disease
0 0
HRU 15 (13) 1 (1)
Unscheduled HRU 15 (13) 1 (1)
Functional status 20 (17) 0
Effect of asthma on ADL 10 (9) 0
School attendance 15 (13) 0
QoL/family outcomes 19 (17) 0
Child’s QoL 9 (8) 0
Caregiver QoL 5 (4) 0
Caregiver functional status 8 (7) 0
Adverse Effects
of therapy
96 (83) 14 (16)
Routinely monitored AE n= 82 Patient/parent- reported 80 (70) 1 (1)
Routine laboratory AE 32 (27) 0
Orophayryngeal infection 28 (24) 0
Ophthalmological events 7 (6) 0
H-P-A axis n = 52 Urine/serum cortisol 52 (44) 0
ACTH stimulation 17 (15) 1 (1)
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attempted to study the impact of ICS on modifying or affecting the
physical consequences of asthma. Two studies, the Childhood
Asthma Management Program (CAMP) [20], and the Inhaled
Steroid Treatment as Regular Therapy in Early Asthma (START)
[21] indicated in their aims that they wished to investigate this
effect. Both measured primary outcomes which we have classified
as related to disease activity, although the CAMP study stated that
their primary outcome (FEV1, %predicted) was a measure of ‘lung
growth’. Investigators acknowledge the difficulties in assessing the
impact of disease, or therapy, on ‘lung growth’ in children with
asthma. It is unlikely that, in a clinical trial, a single measure will
provide the best primary outcome and more methodological
research is needed to identify whether longitudinal outcomes, such
as rate of change in lung function measures, would be a more
appropriate way of assessing lung growth. Although 24 of the
studies that exclusively included children had a treatment period
lasting longer than one year, only three measured outcomes after
the end of the treatment period [20,34,35]. The other 21 studies
represent missed opportunities to investigate the long term effects
of ICS on progression of asthma in children, and this question
should be addressed in future clinical trials.
The long term safety of treatments for asthma has recently been
identified as being of particular importance to patients and
clinicians [36]. Although 83% of studies that only included
children assessed the safety of ICS, the quality with which long
term systemic side effects of ICS were measured was variable. Of
the 24 studies that lasted longer than a year, 21 measured effects
on growth. None of the studies measured the final adult height
attained, despite the fact that this is of most interest to children and
parents. Only 14 studies measured the effect of ICS, when
administered for longer than one year, on hypothalamo-pituitary-
adrenal function, despite the serious and potentially fatal
consequences of this type of adverse reaction [37]. We suggest
that serious systemic side effects should be monitored in all clinical
trials of ICS in children with asthma, so that both the benefits and
risks of these drugs can be appropriately evaluated.
As well as the fact that measurement of long-term efficacy and
safety outcomes is not a requirement of drug regulatory
authorities, there are other reasons why they may not have been
measured in the studies we identified. Diagnostic and technical
problems associated with measurement of lung growth, financial
cost, and problems with patient attrition also hinder the conduct of
long-term studies in children with asthma. Agreement that long-
term outcomes are important, amongst clinicians, patients, and
researchers, could promote the conduct of such studies. There is
also a need for research to identify the most appropriate long-term
outcomes, and the ways in which they should be measured.
The studies we identified are comparable in terms of the
population they include and the interventions which they
compare, and so we feel that our finding of heterogeneity of
outcome selection between studies is valid. Even though we have
reviewed RCTs assessing one aspect of the treatment of childhood
asthma, it is likely that our findings would be similar if we were to
conduct a similar review of, for example, clinical trials of
leukotriene antagonists or long acting beta2 agonists.
We have reviewed outcomes which have been reported rather
than those which were actually measured. Outcome reporting bias
in published RCT reports is common [18,38], and in order to
have evaluated exactly which outcomes had been measured it may
have been more accurate to assess trial protocols. Although
outcome reporting bias may lead to an underestimation of the
frequency with which some outcomes were actually measured, it is
unlikely that it would affect heterogeneity between studies.
Non-uniform outcome selection can make it difficult to design,
interpret, and meta-analyse clinical trials [15,16,39,40], and so a
few collaborations have begun to address the problems of which
outcomes to measure in clinical trials of a variety of paediatric and
adult conditions [9,15]. One solution is a universally-agreed core
set of outcomes which should be measured, as a minimum, in all
clinical trials of a specific condition. Core sets were first designed
by the OMERACT group, which utilises structured consensus
techniques amongst a diverse group of stakeholders and
consumers. Our findings would suggest that a similar initiative
in childhood asthma, with separate consideration of pre-school
and older children, would make an important contribution to
improving clinical research in this very prevalent, chronic disease.
Domain Subdomain 1 Subdomain 2 Outcome
Number (%) of
studies in which
measured as
primary or
secondary
outcome
n=115
Number (%)
of studies
in which
measured as
primary
outcome
n=84a
Growth n = 41 Growth 41 (35) 9 (11)
Lower leg growth 1 (1) 1(1)
Effects of ICS on bone n = 15 Markers of bone turnover 11 (9) 0
Measures of bone density 8 (7) 2 (2)
Abbreviations used in Table 2: ACTH= adrenocorticotropic hormone; ADL =Activities of Daily Living; AE = adverse events; BHR =bronchial hyperresponsiveness;
FEV1 = forced expiratory flow in one second; FVC = forced vital capacity; H-P-A=Hypothalamic-pituitary-adrenal; HRU= health resource utilisation; ICS = inhaled
corticosteroids; IgE = Immunoglobulin E; PEFR =peak expiratory flow rate; QoL =Quality of life.
aOf 84 studies that specified primary outcomes, 5 specified co-primary outcomes, and hence the total number of primary outcomes measured is 89.
bLeukotriene LTC4 in serum and nasal secretions and leukotriene LTE4 in urine.
cInterleukins in serum and sputum.
dEosinophils in serum and sputum, and Eosinophil Cationic Protein in serum and urine.
eIgE in serum.
doi:10.1371/journal.pone.0006276.t002
Table 2. cont.
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Conclusions
We have shown that outcomes in RCTs in children with
asthma, mainly driven by the requirements of drug regulatory
authorities, are focussed on short term disease activity, and
those which may be more relevant to patients are largely
overlooked. Future research must be directed towards deter-
mining the most appropriate and important outcomes to
measure in these trials.
Supporting Information
File S1 Search strategy
Found at: doi:10.1371/journal.pone.0006276.s001 (0.04 MB
PDF)
File S2 List of included studies
Found at: doi:10.1371/journal.pone.0006276.s002 (0.32 MB
PDF)
Figure 2. Change in selection of outcomes between 1988 and 2007. The figure shows trends in the measurement of outcome domains in clinical
trials of inhaled corticosteroid for children with asthma published between 1988 and 2008. Data are presented as a moving window. Each point along the
horizontal axis represents the midpoint of a five year epoch. In each epoch the proportion of studies measuring each individual domain is shown.
doi:10.1371/journal.pone.0006276.g002
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